Frontlight ResearchEarly access
Taking people in United StatesPhase 2
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
Key facts
- Who runs it
- LISCure Biosciences
- Where
- Aurora, Baltimore, Iowa City, Nashville, Rochester, Sacramento, and Seattle, United StatesSee the 7 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 87 people, planned
- Started
- Nov 2025
- Expected to end
- Feb 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LB-P8 low-dose
- LB-P8 high-dose
- Placebo
- Record updated
- 24 October 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Age: 18 to 75 years
- A diagnosis of PSC based on cholangiographic evidence of PSC in accordance with American Association for the Study of Liver Diseases (AASLD) guidelines
- ALP >1.5 times the ULN at screening
- PSC with or without IBD, such as ulcerative colitis or Crohn's disease
- If patients are being administered biologic or advanced therapeutic treatments, immunosuppressants, systemic corticosteroids, obeticholic acid, fibrates, or statins, they must be on a stable dose for ≥3 months prior to, and including, Day 0 and plan to remain on a stable dose throughout the study
- If patients are receiving ursodeoxycholic acid, they must be on a stable dose (not exceeding 23 mg/kg/day) for >3 months prior to screening
- Patient agrees to stop all probiotics for at least 2weeks prior to treatment
- Patient is unable to conceive and/or patient who's partner is unable to become pregnant and/or agree to use effective methods of contraception when engaging in heterosexual intercourse
Who cannot take part
- Treatment with any investigational agents within 3 months or 5 half-lives, whichever is longer prior to treatment or during the study. Gene therapy or other long-lasting investigational agents with unknown half-life is not allowed
- Patients who require chronic use of antibiotics, received antibiotics in the last 1 month, or received Rebyota or Vowst (applicable for patients with Clostridioides difficile infection)
- History of a liver transplant or anticipated need for a liver transplant within 1 year
- Model for end-stage liver disease (MELD) score as below, unless the MELD is driven by anticoagulant therapy, vitamin deficiency, or kidney disease:
- Any history of cholangiocarcinoma, gallbladder cancer, or hepatocellular carcinoma
- History of any malignancy with lymph node or regional metastases within 5 years or current malignancy undergoing active treatment
- In patients with ulcerative colitis, partial Mayo score of >6 or, patients with Crohn's disease if CDAI of >220
- Patients with indwelling biliary drain (or stent), total proctocolectomy with ileal anal pouch, partial large bowel resections or history of small bowel resection
- Active drug (known or suspected use of illicit drugs or drugs of abuse) or alcohol abuse disorder
- Clinically significant and/or active infection
- Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters
- Other causes of liver disease, such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), AIH/PSC overlap syndrome, alpha-1-antitrypsin deficiency, viral hepatitis, iron overload syndrome, Wilson disease, nonalcoholic steatohepatitis, and/or alcohol related liver disease. Additionally, positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV) (detectable HCV RNA in the serum), or human immunodeficiency virus antibodies (anti HIV)
- Subjects with a greater degree of immunosuppression, as evidenced by Alsolute neutrophil count <500 cells/mL or in the investigator's judgement immunosuppressed and at higher risk of infection
- Patients who show evidence of significant worsening of hepatic function will be excluded
- MELD Score of >12 (decompensated cirrhosis) for Part 1 of the study
- MELD Score of >12 for Part 2 of the study
- Small-duct PSC (in the absence of large duct PSC)
- Secondary causes of sclerosing cholangitis including IgG4 associated sclerosing cholangitis
- Chronic kidney injury
- Recent acute cholangitis (within 90 days)
- Female patients who are pregnant, nursing, or planning to become pregnant during the study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- UCHealth University of Colorado HospitalAurora, United StatesContact: UCHealth University of Colorado HospitalNot yet recruiting
- Mercy Medical CenterBaltimore, United StatesContact: Mercy Medical CenterTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: University Of Iowa Hospitals And ClinicsTaking people
- The Vanderbilt ClinicNashville, United StatesContact: The Vanderbilt ClinicTaking people
- Mayo ClinicRochester, United StatesContact: Mayo ClinicNot yet recruiting
- University of California - DavisSacramento, United StatesContact: University of California DavisNot yet recruiting
- Liver Institute NorthwestSeattle, United StatesContact: Liver institute NorthwestTaking people
About the trial
What the trial wants to find out
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
The 3 groups in the trial
- LB-P8 low-doseTreatment being tested
Oral capsule, 1×10\^10 CFU/day
- LB-P8 high-doseTreatment being tested
Oral capsule, 1×10\^11 CFU/day
- PlaceboPlacebo, for comparison
Oral capsule, placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)
- Criteria questions
- Built from NCT06699121, who can take part
- Record updated
- 24 October 2025